Phase II study of a PARP inhibitor, talazoparib, in HER2-metastatic breast cancer (MBC) with a somatic BRCA1/2mutation identified in a cell-free DNA or tumor tissue genotyping assay

被引：0
|
作者：
Vidula, Neelima
Damodaran, Senthil
Bhave, Manali A.
Blouch, Erica
Ogbenna, Ogadinma
Flaum, Lisa E.
Shah, Ami N.
Abramson, Vandana G.
Cristofanilli, Massimo
Sparano, Joseph A.
Ostrer, Harry
Horick, Nora K.
Rugo, Hope S.
Bardia, Aditya
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[3] Emory Univ, Sch Med, Atlanta, GA USA
[4] Massachusetts Gen Hosp, Boston, MA USA
[5] Northwestern Med Grp, Chicago, IL USA
[6] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[7] Vanderbilt Univ, Nashville, TN USA
[8] Weill Cornell Med, New York, NY USA
[9] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA
[10] Albert Einstein Coll Med, Bronx, NY USA
[11] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[12] UCLA, Hlth Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1143
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca).
    Lee, J.
    Annunziata, C. M.
    Minasian, L. M.
    Zujewski, J.
    Prindiville, S. A.
    Kotz, H. L.
    Squires, J.
    Houston, N. D.
    Ji, J. J.
    Yu, M.
    Doroshow, J. H.
    Kohn, E. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
    Litton, Jennifer K.
    Beck, J. Thaddeus
    Jones, Jason M.
    Andersen, Jay
    Blum, Joanne L.
    Mina, Lida A.
    Brig, Raymond
    Danso, Michael
    Yuan, Yuan
    Abbattista, Antonello
    Noonan, Kay
    Niyazov, Alexander
    Chakrabarti, Jayeta
    Czibere, Akos
    Symmans, William F.
    Telli, Melinda L.
    ONCOLOGIST, 2023, 28 (10): : 845 - 855
  • [33] Phase I study of the JAK 1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2 negative metastatic breast cancer (MBC)
    Overmoyer, B.
    Regan, M.
    Schlosnagle, E.
    Bunnell, C.
    Freedman, R.
    Tolaney, S.
    Chen, W.
    Mayer, E.
    Partridge, A.
    Silver, D.
    Winer, E.
    CANCER RESEARCH, 2017, 77
  • [34] A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA)
    Litton, J.
    Ettl, J.
    Hurvitz, S. A.
    Mina, L. A.
    Rugo, H. S.
    Lee, K-H
    Yerushalmi, R.
    Woodward, N.
    Goncalves, A.
    Moreno, F.
    Roche, H.
    Im, Y-H
    Martin, M.
    Bhattacharya, S.
    Peterson, A.
    Hannah, A.
    Eiermann, W.
    Blum, J.
    CANCER RESEARCH, 2017, 77
  • [35] A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)
    Turner, Nicholas C.
    Telli, Melinda L.
    Rugo, Hope S.
    Mailliez, Audrey
    Ettl, Johannes
    Grischke, Eva-Maria
    Mina, Lida A.
    Balmana, Judith
    Fasching, Peter A.
    Hurvitz, Sara A.
    Wardley, Andrew M.
    Chappey, Colombe
    Hannah, Alison L.
    Robson, Mark E.
    CLINICAL CANCER RESEARCH, 2019, 25 (09) : 2717 - 2724
  • [36] Multicenter phase II trial of the novel compound PM01183 (P) in BRCA1/2-associated or unselected metastatic breast cancer (MBC)
    Isakoff, S. J.
    Cruz, C.
    Garber, J.
    Lluch, A.
    Perez Fidalgo, J. A.
    Tung, N.
    Fernandez, C.
    Kahatt, C.
    Szyldergemajn, S.
    Soto Matos-Pita, A.
    Baselga, J.
    Balmana, J.
    CANCER RESEARCH, 2013, 73
  • [37] SU2C phase Ib study of the PI3Kα inhibitor BYL719 with letrozole in ER+/HER2-metastatic breast cancer (MBC).
    Mayer, Ingrid A.
    Abramson, Vandana Gupta
    Balko, Justin M.
    Sanders, Melinda
    Juric, Dejan
    Li, Yisheng
    Ley, Lewis Cant
    Winer, Eric P.
    Arteag, Carlos L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study.
    Telli, Melinda L.
    Litton, Jennifer Keating
    Beck, Joseph Thaddeus
    Jones, Jason M.
    Andersen, Jay
    Mina, Lida A.
    Brig, Raymond
    Danso, Michael A.
    Yuan, Yuan
    Symmans, William Fraser
    Abbattista, Antonello
    Noonan, Kay
    Mata, Marielena
    Laird, Douglas
    Blum, Joanne Lorraine
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Antitumor activity of trabectedin and lurbinectedin in germline BRCA2 carriers with metastatic breast cancer (MBC) as compared to BRCA1 carriers: Analysis of two phase II trials.
    Gelpi, Judith Balmana
    Lubinski, Jan Antoni
    Arun, Banu
    Byrski, Tomasz
    Telli, Melinda L.
    Isakoff, Steven J.
    Fernandez, Cristian
    Lardelli, Pilar
    Kahatt, Carmen Maria
    Soto-Matos, Arturo
    Delaloge, Suzette
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study
    Boni, V
    Pistilli, B.
    Brana, I
    Shapiro, G., I
    Trigo, J.
    Moreno, V
    Castellano, D.
    Fernandez, C.
    Kahatt, C.
    Alfaro, V
    Siguero, M.
    Zeaiter, A.
    Longo, F.
    Zaman, K.
    Anton, A.
    Paredes, A.
    Huidobro, G.
    Subbiah, V
    ESMO OPEN, 2022, 7 (05)
12345